These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 19412697

  • 1. [Third generation beta-blockers: current state of research on vasodilating beta-blockers].
    Ladage D, Reidenbach C, Lichtenthal A, Schwinger R, Brixius K.
    Wien Med Wochenschr; 2009; 159(7-8):211-8. PubMed ID: 19412697
    [Abstract] [Full Text] [Related]

  • 2. Nitric oxide mechanisms of nebivolol.
    Maffei A, Lembo G.
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [Abstract] [Full Text] [Related]

  • 3. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE, DiGennaro F, Giani JF, Dominici FP.
    Vasc Health Risk Manag; 2012 Aug; 8():151-60. PubMed ID: 22454559
    [Abstract] [Full Text] [Related]

  • 4. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D, Papademetriou V.
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [Abstract] [Full Text] [Related]

  • 5. Nebivolol: a review.
    Cockcroft J.
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [Abstract] [Full Text] [Related]

  • 6. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.
    Drugs; 2010 Apr; 70(1):41-56. PubMed ID: 20030424
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
    Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F, Angerosa M.
    J Hypertens; 2010 May; 28(5):1007-19. PubMed ID: 20411618
    [Abstract] [Full Text] [Related]

  • 8. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C.
    J Am Coll Cardiol; 2009 Apr 28; 53(17):1532-8. PubMed ID: 19389564
    [Abstract] [Full Text] [Related]

  • 9. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H, Lavie CJ, Ventura HO.
    Postgrad Med; 2012 Mar 28; 124(2):7-15. PubMed ID: 22437211
    [Abstract] [Full Text] [Related]

  • 10. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review.
    Carella AM, Antonucci G, Conte M, Di Pumpo M, Giancola A, Antonucci E.
    Curr Diabetes Rev; 2010 Jul 28; 6(4):215-21. PubMed ID: 20459394
    [Abstract] [Full Text] [Related]

  • 11. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E, Rizzoni D.
    Drugs; 2007 Jul 28; 67(8):1097-107. PubMed ID: 17521213
    [Abstract] [Full Text] [Related]

  • 12. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension.
    Zepeda RJ, Castillo R, Rodrigo R, Prieto JC, Aramburu I, Brugere S, Galdames K, Noriega V, Miranda HF.
    Basic Clin Pharmacol Toxicol; 2012 Nov 28; 111(5):309-16. PubMed ID: 22703478
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM, Fici F, Mascagni F.
    Am J Cardiovasc Drugs; 2008 Nov 28; 8(1):35-44. PubMed ID: 18303936
    [Abstract] [Full Text] [Related]

  • 14. Nebivolol: third-generation beta-blockade.
    de Boer RA, Voors AA, van Veldhuisen DJ.
    Expert Opin Pharmacother; 2007 Jul 28; 8(10):1539-50. PubMed ID: 17661735
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol.
    Giles TD.
    Am J Med; 2010 Jul 28; 123(7 Suppl 1):S16-20. PubMed ID: 20609694
    [Abstract] [Full Text] [Related]

  • 18. Effects of nebivolol on human platelet aggregation.
    Falciani M, Rinaldi B, D'Agostino B, Mazzeo F, Rossi S, Nobili B, Rossi F, Filippelli A.
    J Cardiovasc Pharmacol; 2001 Dec 28; 38(6):922-9. PubMed ID: 11707696
    [Abstract] [Full Text] [Related]

  • 19. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J, Faülhaber HD.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():77-82. PubMed ID: 15700490
    [Abstract] [Full Text] [Related]

  • 20. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.